Surprisingly, several, though not all, studies have shown a positive relationship between serum adiponectin (ADPN) and mortality rate. In order to deeply address direction and strength of this paradoxical association, we carried out a systematic review and meta-analysis (MA) of prospective studies present in MEDLINE, Cochrane Library and Scopus by December, 1st 2017, with ADPN being the exposure and all-cause (AC) and cardiovascular (CV) mortality the outcomes. We performed random effect MA to pool individual hazard ratios (HRs; 95% CIs). To address the role of Natriuretic Peptides (NPs), known to increase both ADPN expression and mortality rate, a MA focused only on studies reporting HRs before and after NPs adjustment was also carried out. We assessed study heterogeneity by Q statistic and then performed meta-regressions considering male percentage, age, BMI, eGFR and clinical setting (general population, type 2 diabetes, CV disease, dialysis) as study level covariates. We identified 56 (n=64,775 subjects) and 30 (n=48,439) studies for AC and CV mortality, respectively. Heterogeneity across studies was observed for both outcomes (Q-test p<0.01). HRs, expressed as 1 SD increment of total ADPN, were 1.24 (1.17-1.30) and 1.28 (1.20-1.37) for AC and CV mortality, respectively. MA restricted to the 12 studies (n=19,010) reporting NPs data showed HRs for AC mortality equal to 1.24 (1.16-1.34) and 1.13 (1.06-1.21) without and with NPs adjustment, respectively (p<0.between HRs, when their correlation was >0.1). For CV mortality (6 studies, n=15,252), HRs were 1.21 (1.10-1.33) and 1.15 (1.06-1.24) without and with NPs adjustment, respectively (p<0.between HRs, when their correlation was >0.8). Male percentage, age, BMI, eGFR and clinical setting did not explain the observed heterogeneity among studies. Our results confirm the existence of a paradoxical association between high ADPN levels and increased mortality rate. Such paradox seems to be only partly explained by NPs levels.

Disclosure

M. Scarale: None. A. Fontana: None. V. Trischitta: None. M. Copetti: None. C. Menzaghi: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.